ArticleCureus2025
Peroneal Nerve Palsy With Foot Drop: A Rare Manifestation of Oxaliplatin Toxicity.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxaliplatin is a platinum-based chemotherapy drug that is distinguished from others in its class by its neurotoxicity. This toxicity most commonly presents as a peripheral neuropathy with sensory symptoms, and less frequently as motor or autonomic disorders. Peroneal nerve palsy is a mononeuropathy presenting with foot drop and may result from multiple causes. Its occurrence in association with chemotherapy, particularly oxaliplatin, is rare. We report two cases of peroneal nerve palsy associated with oxaliplatin treatment. Case 1 involves a 73-year-old female with stage IV pancreatic adenocarcinoma who developed a left foot drop after four cycles of modified FOLFIRINOX (oxaliplatin 85 mg/m²). Neurological examination revealed distal weakness (3/5) without additional deficits. Electromyography confirmed axonal and demyelinating injury of the left common peroneal nerve (CPN). Other causes were ruled out. Following oxaliplatin discontinuation, the deficit completely resolved. Case 2 involves a 62-year-old male diagnosed with adenocarcinoma of the gastroesophageal junction who underwent neoadjuvant chemoradiotherapy with carboplatin (AUC 2) plus paclitaxel (50 mg/m²) and presented with metastatic disease five months later. After four cycles of FOLFOX (oxaliplatin 85 mg/m²), he developed a painless right foot drop with isolated motor deficit (0/5). Laboratory tests, brain CT, and spine MRI excluded alternative causes. Disease progression precluded further evaluation, and the patient died before the clinical course of the palsy could be assessed. These two cases highlight the potential of oxaliplatin-induced neurotoxicity to manifest as an isolated peroneal nerve palsy with foot drop. Given that only six cases of this condition have been described in the literature so far, further case reports are essential to better characterize risk factors, clinical course, and outcomes of this rare complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.